GB202100976D0 - Treatment - Google Patents

Treatment

Info

Publication number
GB202100976D0
GB202100976D0 GBGB2100976.6A GB202100976A GB202100976D0 GB 202100976 D0 GB202100976 D0 GB 202100976D0 GB 202100976 A GB202100976 A GB 202100976A GB 202100976 D0 GB202100976 D0 GB 202100976D0
Authority
GB
United Kingdom
Prior art keywords
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2100976.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RIOTECH PHARMACEUTICALS Ltd
Original Assignee
RIOTECH PHARMACEUTICALS Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RIOTECH PHARMACEUTICALS Ltd filed Critical RIOTECH PHARMACEUTICALS Ltd
Priority to GBGB2100976.6A priority Critical patent/GB202100976D0/en
Publication of GB202100976D0 publication Critical patent/GB202100976D0/en
Priority to PCT/GB2022/050194 priority patent/WO2022157519A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB2100976.6A 2021-01-25 2021-01-25 Treatment Ceased GB202100976D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2100976.6A GB202100976D0 (en) 2021-01-25 2021-01-25 Treatment
PCT/GB2022/050194 WO2022157519A1 (en) 2021-01-25 2022-01-25 Treatment of coronavirus infection

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2100976.6A GB202100976D0 (en) 2021-01-25 2021-01-25 Treatment

Publications (1)

Publication Number Publication Date
GB202100976D0 true GB202100976D0 (en) 2021-03-10

Family

ID=74859054

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2100976.6A Ceased GB202100976D0 (en) 2021-01-25 2021-01-25 Treatment

Country Status (2)

Country Link
GB (1) GB202100976D0 (en)
WO (1) WO2022157519A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201016880D0 (en) 2010-10-07 2010-11-17 Riotech Pharmaceuticals Ltd Phosphodiesterase inhibitors

Also Published As

Publication number Publication date
WO2022157519A1 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
GB202108224D0 (en) Treatment
GB202103122D0 (en) Treatment
GB202016058D0 (en) Therapeautic treatment
GB202003722D0 (en) Treatment
GB202002711D0 (en) Treatment
GB202116743D0 (en) Treatment
GB202114373D0 (en) Treatment
GB202109815D0 (en) Treatment
GB202109812D0 (en) Treatment
GB202104666D0 (en) COVID-19 treatment
GB202104416D0 (en) Treatment reginmens
GB202103957D0 (en) Treatment
GB202102488D0 (en) Treatment
GB202102369D0 (en) Treatment
GB202102373D0 (en) Treatment
GB202102366D0 (en) Treatment
GB202102410D0 (en) Treatment
GB202101897D0 (en) Treatment
GB202101875D0 (en) Treatment
GB202101210D0 (en) Treatment
GB202101213D0 (en) Treatment
GB202101211D0 (en) Treatment
GB202101212D0 (en) Treatment
GB202100976D0 (en) Treatment
GB202020157D0 (en) Treatment

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)